NEW YORK (TheStreet) -- Occulus Innovative Sciences (OCLS) shares are up 3.47% to $1.79 in after-hours trading on Thursday following the release of the healthcare company's fourth quarter earnings results after the closing bell today.
The Petaluma, CA-based company reported that fourth quarter revenue grew 37% to $4 million from $2.9 million a year ago.
The company also reported a net loss of 11 cents per diluted share, also topping analysts' 19 cent per share loss expectations.
TheStreet Ratings team rates OCULUS INNOVATIVE SCIENCES as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate OCULUS INNOVATIVE SCIENCES (OCLS) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share."
Highlights from the analysis by TheStreet Ratings Team goes as follows: